Ordina per
Keyphrases
Systemic Lupus Erythematosus
100%
Longitudinal Analysis
100%
Hispanic Patients
100%
Anti-CD20 Therapy
100%
Rituximab
75%
Lupus Nephritis
75%
Immunosuppressive Therapy
50%
Mexican Population
50%
Skin Involvement
50%
Musculoskeletal Involvement
50%
Immune Thrombocytopenia
50%
SLE Disease Activity Index (SLEDAI)
50%
Disease Flare
25%
Nineteen
25%
Platelet Count
25%
Serum Sickness
25%
Conventional Therapy
25%
Leukocytopenia
25%
Lupus
25%
MabThera
25%
Inflammatory Polyarthritis
25%
Baseline Predictors
25%
Arthritis
25%
Pulmonary Infection
25%
Effective Strategies
25%
Remission
25%
Clinical Improvement
25%
Rituximab Therapy
25%
Complete Renal Response
25%
Partial Response
25%
Thrombocytopenia
25%
Disease Activity
25%
Predicting Disease
25%
Oral Prednisone
25%
Nursing and Health Professions
Longitudinal Analysis
100%
Systemic Lupus Erythematosus
100%
Rituximab
100%
Lupus Erythematosus Nephritis
60%
Immunosuppressive Treatment
40%
Musculoskeletal System
40%
Idiopathic Thrombocytopenic Purpura
40%
SLEDAI
40%
Disease Activity
20%
Prednisone
20%
Efficacy
20%
Thrombocytopenia
20%
Serum Sickness
20%
Disease Exacerbation
20%
Polyarthritis
20%
Accident Prevention
20%
Remission
20%
Platelet Count
20%
Leukopenia
20%
Infusion
20%
Lung Infection
20%
Arthritis
20%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
CD20
100%
Rituximab
100%
Lupus Nephritis
60%
Immunosuppressive Treatment
40%
Musculoskeletal System
40%
SLEDAI
40%
Idiopathic Thrombocytopenic Purpura
40%
Disease Exacerbation
20%
Lupus Erythematosus
20%
Thrombocytopenia
20%
Platelet
20%
Infusion
20%
Disease Activity
20%
Oral
20%
Inflammatory Polyarthropathy
20%
Prednisone
20%
Arthritis
20%
Lung Infection
20%
Leukopenia
20%
Serum Sickness
20%
Immunology and Microbiology
Rituximab
100%
CD20
100%
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
80%
Nephritis
60%
Idiopathic Thrombocytopenic Purpura
40%
Musculoskeletal System
40%
Arthritis
20%
Serum Sickness
20%
Immunosuppressive Therapy
20%
Polyarthritis
20%
Prednisone
20%
Platelet Count
20%
Immunosuppressive Drug
20%
Infectious Disease
20%
Infection
20%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Rituximab
100%
Lupus Erythematosus Nephritis
60%
Immunosuppressive Agent
40%
Idiopathic Thrombocytopenic Purpura
40%
Disease Exacerbation
20%
Disease Activity
20%
Prednisone
20%
Thrombocytopenia
20%
Remission
20%
Polyarthritis
20%
Lung Infection
20%
Leukopenia
20%
Arthritis
20%
Serum Sickness
20%